<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>The retrospective study for rheumatic disease patients was conducted between 27 December 2020 and 31 August 2021 at Pauls Stradiņš Clinical University Hospital, in the largest centre of Rheumatology in Latvia with the aim of assessing the impact of vaccination against SARS-CoV-2 for rheumatic disease patients. From the hospital’s local medical electronic system, we collected demographic data, disease activity, comorbidities, data regarding vaccines and their side effects for 422 rheumatic disease patients. Most of them, 377 (89.3%), had inflammatory arthritis or a rare rheumatic disease and the most common disease was rheumatoid arthritis 30.1%; 26.5% of all patients were in remission. csDMARDs (conventional synthetic disease modified antirheumatic drugs) were used in 47.2%, biological DMARDs in 51%, and immunosuppressive medicines in 4.2% cases. The most commonly used vaccine was BNT162b2, for 49.05% patients. The main side effect after vaccination was pain in the injection site, for 16.1% patients. 36.7% of patients had no side effects after vaccination. 8.7% of patients had a flare of disease after the vaccination process. The most common comorbidity was cardiovascular diseases, for 38.7% of patients. Mild side effects, and a small percentage of flare-up of a rheumatic disease demonstrated the safety of vaccination against SARS-CoV-2 in the rheumatic disease patient group.</p>
</abstract>

The retrospective study for rheumatic disease patients was conducted between 27 December 2020 and 31 August 2021 at Pauls Stradiņš Clinical University Hospital, in the largest centre of Rheumatology in Latvia with the aim of assessing the impact of vaccination against SARS-CoV-2 for rheumatic disease patients. From the hospital’s local medical electronic system, we collected demographic data, disease activity, comorbidities, data regarding vaccines and their side effects for 422 rheumatic disease patients. Most of them, 377 (89.3%), had inflammatory arthritis or a rare rheumatic disease and the most common disease was rheumatoid arthritis 30.1%; 26.5% of all patients were in remission. csDMARDs (conventional synthetic disease modified antirheumatic drugs) were used in 47.2%, biological DMARDs in 51%, and immunosuppressive medicines in 4.2% cases. The most commonly used vaccine was BNT162b2, for 49.05% patients. The main side effect after vaccination was pain in the injection site, for 16.1% patients. 36.7% of patients had no side effects after vaccination. 8.7% of patients had a flare of disease after the vaccination process. The most common comorbidity was cardiovascular diseases, for 38.7% of patients. Mild side effects, and a small percentage of flare-up of a rheumatic disease demonstrated the safety of vaccination against SARS-CoV-2 in the rheumatic disease patient group.

Outcomes of Vaccination Against SARS-CoV-2 in Patients with Rheumatic Diseases in Latvia

Pauls Stradiņš Clinical University Hospital

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

This work is licensed under the Creative Commons Attribution 4.0 International License.

The retrospective study for rheumatic disease patients was conducted between 27 December 2020 and 31 August 2021 at Pauls Stradiņš Clinical University...

Outcomes of Vaccination Against SARS-CoV-2 in Patients with Rheumatic Diseases in Latvia

Pubblicato online: 04 mar 2024

Pagine: 22 - 28

Ricevuto: 04 ott 2022

Accettato: 12 gen 2024

DOI: https://doi.org/10.2478/prolas-2024-0004

Parole chiave
arthritis, rare diseases, vaccination against COVID-19, comorbidities

© 2024 Inita Buliņa et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Outcomes of Vaccination Against SARS-CoV-2 in Patients with Rheumatic Diseases in Latvia

Pubblicato online: 04 mar 2024

Pagine: 22 - 28

Ricevuto: 04 ott 2022

Accettato: 12 gen 2024

DOI: https://doi.org/10.2478/prolas-2024-0004

Parole chiavearthritis, rare diseases, vaccination against COVID-19, comorbidities

© 2024 Inita Buliņa et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Parole chiave
arthritis, rare diseases, vaccination against COVID-19, comorbidities